Feature|Videos|April 21, 2026

The Trends Shaping a CDMO Partnership

Key Takeaways

  • Identify the key industry trends driving the shift from transactional CDMO relationships to long-term, strategic partnerships.
  • Describe how an integrated, single-source CDMO model can reduce risk, accelerate timelines, and improve product quality.
SHOW MORE

The CDMO landscape is shifting toward long-term strategic partnerships as drug modalities grow more complex and supply chain pressures mount. Noritsugu Fujita, Division President of Pharmaceutical Solutions Division at Terumo, explains how an integrated, single-source model for parenteral drug development aims to streamline the path to a patient-ready product.

Sponsored by Terumo

The CDMO industry is undergoing a fundamental transformation, driven by the growing complexity of new drug modalities including biologics, DNA medicines, RNA medicines, and cell and gene therapies. Noritsugu Fujita, Division President of Pharmaceutical Solutions Division at Terumo, highlights the need for more resilient, reliable supply chains that move beyond fragmented, transactional relationships. One approach gaining traction is the fully integrated CDMO model, which consolidates the entire parenteral drug development journey—from formulation and sterile fill-finish to device assembly, labeling, and final packaging—under a single partner. Fujita emphasizes aligning drug, device, and patient interaction considerations early in development, with the goal of proactively addressing compatibility challenges before they affect timelines or regulatory submissions. Aside from mitigating these challenges, consolidation with a single partner can help customers reduce their carbon footprint and simplify their supply chains.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.